Abstract:Amyloid beta (Aβ) is the main component of the amyloid plaques that accumulate in the brains of Alzheimer patients. The present study was conducted to investigate whether the combined treatment with selenium (Se) and zinc (Zn) offers more beneficial effects than that provided by either of them alone in reversing Aβ 25–35 -induced neurotoxicity in PC12 cells. Cells were pretreated with 0.1 μmol/L of Se and Zn for 4 h, after treated with 10 mmol/L Aβ 25–35 for 24 h. Cells were divided into control and five treated groups, and received either 10 mmol/L Aβ 25–35, 10 mmol/L Aβ 25–35 + 0.1 μmol/L Se, 10 mmol/L Aβ 25–35 + 0.1 μmol/L Zn, 10 mmol/LAβ 25–35 + 0.1 μmol/L Se + 0.1 μmol/L Zn, or 0.1 μmol/L Se + 0.1 μmol/L Zn. The result showed that cell viability was decreased in MTT metabolic rate; LDH release and MDA, H 2 O 2 , and NO levels were increased and the GSK-3β and phosphorylated tau protein level were increased in Aβ 25–35 -treated group ( P < 0.05 or P < 0.01), which whole changes were attenuated by Se and Zn and Se combined Zn. In order to evaluate whether the Se and Zn have an effect on processing pathway of amyloid precursor protein (APP), we examined the activity of γ-secretase in primary cultured cortical neuron cells. ELISA analysis showed that Se and Zn could inhibit the activity of γ-secretase. Then we also investigated the effect of Se and Zn on the Aβ 1–40 concentration and APP-N-terminal fragment expression from APP695 stably transfected Chinese hamster ovary (CHO) cells. APP695 stably transfected CHO cells were treated with 0.1 μmol/L Se and Zn; cells were divided into control and four treated groups, which received either 0.5 M DAPT, 0.1 μmol/L Se, 0.1 μmol/L Zn, or 0.1 μmol/L Se + 0.1 μmol/L Zn. Se and Zn could decrease Aβ 1–40 production and increase the APP-N-terminal fragment protein expression. These experiments indicate that Se and Zn have a protective effect on AD pathology that a possible mechanism is inhibiting the activity of γ-secretase to decreasing Aβ 1–40 production further influencing the APP processing. Altogether, our findings may provide a novel therapeutic target to treat AD sufferers.

SELENOK-dependent CD36 palmitoylation regulates microglial functions and Aβ phagocytosis

Selenium Restores Synaptic Deficits by Modulating NMDA Receptors and Selenoprotein K in an Alzheimer's Disease Model

Different Effects and Mechanisms of Selenium Compounds in Improving Pathology in Alzheimer's Disease

Selenoprotein W modulates tau homeostasis in an Alzheimer's disease mouse model

Selenium and Zinc against Aβ 25–35 -Induced Cytotoxicity and Tau Phosphorylation in PC12 Cells and Inhibits γ-cleavage of APP

Roles of Selenoproteins in Brain Function and the Potential Mechanism of Selenium in Alzheimer’s Disease

Reversal of Lipid Metabolism Dysregulation by Selenium and Folic Acid Co-Supplementation to Mitigate Pathology in Alzheimer’s Disease

Selenoprotein SELENOK Enhances the Migration and Phagocytosis of Microglial Cells by Increasing the Cytosolic Free Ca2+ Level Resulted from the Up-Regulation of IP3R.

Selenium-core Nanozymes Dynamically Regulates Aβ & Neuroinflammation Circulation: Augmenting Repair of Nervous Damage

Biogenic Selenium Nanoparticles Attenuate Aβ25–35-Induced Toxicity in PC12 Cells via Akt/CREB/BDNF Signaling Pathway

Biogenic Selenium Nanoparticles Attenuate Aβ 25–35 -Induced Toxicity in PC12 Cells via Akt/CREB/BDNF Signaling Pathway

Comparative Serum Proteomic Analysis of the Effects of Sodium Selenate on a Mouse Model of Alzheimer’s Disease

Selenepezil, a Selenium-Containing Compound, Exerts Neuroprotective Effect via Modulation of the Keap1-Nrf2-ARE Pathway and Attenuates Aβ-Induced Cognitive Impairment in Vivo.

Selenomethionine Improves Mitochondrial Function by Upregulating Mitochondrial Selenoprotein in a Model of Alzheimer’s Disease

His-Rich Domain of Selenoprotein P Ameliorates Neuropathology and Cognitive Deficits by Regulating TrkB Pathway and Zinc Homeostasis in an Alzheimer Model of Mice.

Orally administered selenium-containing α-D-1,6-glucan and α-D-1,6-glucan relief early cognitive deficit in APP/PS1 mice

Sodium Selenate Activated Wnt/β-catenin Signaling and Repressed Amyloid-Β Formation in a Triple Transgenic Mouse Model of Alzheimer's Disease

EFFECTS OF SELENIUM AND ZINC ON AMYLOID PRECURSOR PROTEIN ENZYME PATHWAYS IN SENILE DEMENTIA MICE

Selenium-enriched foods and their ingredients: As intervention for the vicious cycle between autophagy and overloaded stress responses in Alzheimer's disease

The Role of Gut Microbiota in the Neuroprotective Effects of Selenium in Alzheimer's Disease.

The Role and Mechanism of TPK‐SENP1 Signaling Axis in Regulating Aβ Deposition in Alzheimer’s Disease